<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01715519</url>
  </required_header>
  <id_info>
    <org_study_id>VII-IT-05</org_study_id>
    <nct_id>NCT01715519</nct_id>
  </id_info>
  <brief_title>Vilazodone for the Treatment of Posttraumatic Stress Disorder</brief_title>
  <official_title>A Double-blind, Placebo-controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southern California Institute for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Southern California Institute for Research and Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether vilazodone is effective in the treatmen of
      Posttraumatic Stress Disorder (PTSD)and co-morbid mild or more depression.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PTSD symptoms</measure>
    <time_frame>four months</time_frame>
    <description>PCL-C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PTSD Diagnosis</measure>
    <time_frame>4 months</time_frame>
    <description>CAPS</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>four months</time_frame>
    <description>BDI-II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep</measure>
    <time_frame>4 months</time_frame>
    <description>PSQI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>4 months</time_frame>
    <description>HSCL-25</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Biomarkers</measure>
    <time_frame>four months</time_frame>
    <description>serum</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>PTSD</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Treatment (Viibryd)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/day 1 to 7; 20 mg/day 8 to 14; 40 mg/day week 3 to end week 12. Subjects will then be tapered off vilazodone as follows: 20 mg/day week 13, 10 mg/day, week 14 and no medication during week 15.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will be compared to the treatment group (viibryd)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment (Viibryd)</intervention_name>
    <arm_group_label>Treatment (Viibryd)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Vilazodone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must satisfy DSM-IV diagnostic criteria for chronic PTSD

          -  Evidence of PTSD disease base upon one or more of the following:

          -  Mild or greater depression on the Beck Depression Inventory -II (BDI-II, score&gt; 12).

          -  May have other symptom co-morbid with PTSD (e.g., anxiety or somatic pain)

          -  Ability to comprehend and satisfactorily comply with protocol required and signed
             written informed consent prior to entering study procedure

          -  May be in psychotherapy if initiated at least three months prior to the screening
             visit. Subject must not discontinue or otherwise alter therapy during the study.

          -  Subject may not have taken any psychopharmacological medications within 7 days prior
             to Baseline visit.

          -  Negative urine pregnancy test at screening visit and for the duration of the study for
             women of childbearing potential.

        Exclusion Criteria:

          -  Patients with a concurrent DSM-IV Axis I diagnosis in any of the following categories:

               1. Delirium, Dementia, Amnestic and other Cognitive disorders

               2. Lifetime Schizophrenia and other Psychotic Disorders

               3. lifetime Bipolar I Disorder

               4. Bipolar-II Disorder with an episode of hypomania within the last year

               5. Alcohol or Substance Dependence or Abuse (excluding nicotine) in one month prior
                  to the Screening Visit

               6. Any other concurrent Axis I Disorder (including Major Depressive Disorder) must
                  be secondary to the primary diagnosis of PTSD.

          -  Decisional incapacity (dementia)

          -  Use of centrally acting medications that potentially have an effect on biological
             expression

          -  Chronic pain levels requiring use of any opiate medications

          -  Known exposure to chemicals of physical traumas that cause neuropsychiatric sequelae

          -  Past chronic PTSD

          -  History of 2 or more treatment failures on SSRIs given primarily for the treatment of
             PTSD, in adequate does at the Investigator's opinion, for at least 8 weeks

          -  History of intolerance or hypersensitivity to SSRI's

          -  History of seizures

          -  Significant risk of committing suicide, or are homicidal or violent and in the
             Investigator's opinion in significant imminent risk of hurting others

          -  Treated with depot-neuroleptic within 3 months or MAO inhibitors within 30 day prior
             to Baseline visit

          -  Received ECT within 3 months prior to Screening visit

          -  Pregnant or nursing, women of childbearing potential who are sexually active and do
             not use adequate contraception, or who are judged to be unreliable in their use of
             contraception

          -  Positive urine drug screen, unless proven to be prescribed for a short-term course of
             treatment. Drug screen must be repeated at least 7 days after the last dose of
             prescription medication containing narcotics

          -  A medical condition, in the Investigator's opinion, would expose them to an increased
             risk of a significant adverse event or interfere with assessments of safety and
             efficacy during the course of the trial

          -  Requiring concomitant treatment with any psychotropic drug (except zolpidem for sleep)

          -  Plans to initiate or terminate any form of psychotherapy or behavior therapy during
             the study

          -  Receiving disability payments (&gt; 50 % service connections or total Social Security) or
             who are involved in litigation for PTSD or other psychiatric illnesses.

          -  Unable to speak, read, and understand English or are judged by the investigator to be
             unable or unlikely to follow the study protocol and complete all scheduled visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Veterans Affairs Long Beach Healthcare System</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Nebraska Western-Iowa Healthcare Systems</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2012</study_first_submitted>
  <study_first_submitted_qc>October 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2012</study_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Southern California Institute for Research and Education</investigator_affiliation>
    <investigator_full_name>Michael Hollifield, MD</investigator_full_name>
    <investigator_title>Director of Program for Traumatic Stress</investigator_title>
  </responsible_party>
  <keyword>Vilazodone</keyword>
  <keyword>PTSD</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Stress Disorders, Traumatic</mesh_term>
    <mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vilazodone Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

